Literature DB >> 15265973

Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review.

R W Field1, B J Smith, C E Platz, R A Robinson, J S Neuberger, C P Brus, C F Lynch.   

Abstract

Because few studies have assessed the accuracy of lung cancer histologic diagnoses reported by state cancer registries, we examined whether the Iowa Surveillance, Epidemiology, and End Results Cancer Registry (i.e., the Iowa Cancer Registry)-reported lung cancer histologic diagnoses were reliable. We investigated agreement between lung cancer histologic types reported for 413 patients with lung cancer by the Iowa Cancer Registry and those obtained through an independent review of diagnostic slides. Among lung cancer histologic types, small-cell carcinoma had the highest sensitivity (94.1%, 95% confidence interval [CI] = 85.6% to 98.4%), positive predictive value (94.1%, 95% CI = 85.6% to 98.4%), negative predictive value (98.8%, 95% CI = 96.9% to 99.7%), and highest percent exact agreement (98.0%, 95% CI = 96.6% to 99.4%). The lowest sensitivity (21.9%, 95% CI = 9.3% to 40.0%) and positive predictive value (23.3%, 95% CI = 9.9% to 42.3%) were noted for large-cell carcinoma, probably because other more specific features of adenocarcinoma or squamous carcinoma were absent. Adenocarcinoma had the lowest specificity (84.4%, 95% CI = 79.0% to 88.9%), negative predictive value (85.2%, 95% CI = 79.9% to 89.6%), and percent exact agreement (82.9%, 95% CI = 79.2% to 86.6%). Samples collected by cytologic examination (odds ratio [OR] = 2.4, 95% CI = 1.1 to 5.2) or biopsy examination (OR = 2.2, 95% CI = 1.1 to 4.2) were more likely to be misclassified than samples obtained via resection. Thus, the histologic type obtained by the Iowa Cancer Registry is reasonably reliable, but independent slide review is needed for precise histologic typing of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265973     DOI: 10.1093/jnci/djh189

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  30 in total

1.  Neither inadequacy of biopsy nor inaccuracy of reporting predict non-response to small-cell carcinoma chemotherapy.

Authors:  T N Doig; W A Wallace; D M Salter; H Monaghan; E Brown
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

2.  Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results program.

Authors:  Brian Shuch; Jonathan N Hofmann; Maria J Merino; Jeffrey W Nix; Srinivas Vourganti; W Marston Linehan; Kendra Schwartz; Julie J Ruterbusch; Joanne S Colt; Mark P Purdue; Wong-Ho Chow
Journal:  Urol Oncol       Date:  2013-02-28       Impact factor: 3.498

3.  Use of glucosamine and chondroitin and lung cancer risk in the VITamins And Lifestyle (VITAL) cohort.

Authors:  Theodore M Brasky; Johanna W Lampe; Christopher G Slatore; Emily White
Journal:  Cancer Causes Control       Date:  2011-06-25       Impact factor: 2.506

4.  Associations of long-chain ω-3 fatty acids and fish intake with endometrial cancer risk in the VITamins And Lifestyle cohort.

Authors:  Theodore M Brasky; Marian L Neuhouser; David E Cohn; Emily White
Journal:  Am J Clin Nutr       Date:  2014-02-05       Impact factor: 7.045

5.  Genetic testing for lung cancer: reflex versus clinical selection.

Authors:  Paul A Bunn; Robert C Doebele
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

Review 6.  The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship.

Authors:  Máire A Duggan; William F Anderson; Sean Altekruse; Lynne Penberthy; Mark E Sherman
Journal:  Am J Surg Pathol       Date:  2016-12       Impact factor: 6.394

7.  Long-Term, Supplemental, One-Carbon Metabolism-Related Vitamin B Use in Relation to Lung Cancer Risk in the Vitamins and Lifestyle (VITAL) Cohort.

Authors:  Theodore M Brasky; Emily White; Chi-Ling Chen
Journal:  J Clin Oncol       Date:  2017-08-22       Impact factor: 44.544

8.  Risk factors for lung cancer in Iowa women: implications for prevention.

Authors:  John S Neuberger; Jonathan D Mahnken; Matthew S Mayo; R William Field
Journal:  Cancer Detect Prev       Date:  2006-04-03

9.  Long-term use of supplemental multivitamins, vitamin C, vitamin E, and folate does not reduce the risk of lung cancer.

Authors:  Christopher G Slatore; Alyson J Littman; David H Au; Jessie A Satia; Emily White
Journal:  Am J Respir Crit Care Med       Date:  2007-11-07       Impact factor: 21.405

10.  Non-steroidal anti-inflammatory drugs and endometrial cancer risk in the VITamins And Lifestyle (VITAL) cohort.

Authors:  Theodore M Brasky; Kirsten B Moysich; David E Cohn; Emily White
Journal:  Gynecol Oncol       Date:  2012-10-09       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.